A Trial of Grazax in Subjects With Hayfever

The trial is performed to evaluate the efficacy and safety of specific immunotherapy with Grazax for treatment of grass pollen induced allergy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergy Hypersensitivity Immune System Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CompleWare Corporation

Iowa City, Iowa, 52244-3090, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

History of grass pollen allergy
Positive skin prick test to grass
Positive specific IgE to grass

Exclusion criteria

FEV1 <70% of predicted value

Treatment and study plan

GRAZAX

Drug

Tablets 75,000 SQT and matching placebo. One tablet daily.

Primary outcomes

Recording of allergy symptoms

Time frame: Grass pollen season 2007

Sponsors and collaborators

Lead sponsor

ALK-Abelló A/S

Industry

Registry information

Official study title

A Phase III Trial Assessing the Efficacy and Safety of Grazax in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Jan 12, 2007
Registry last updated: Jun 24, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed